Regeneron Pharmaceuticals Inc (LTS:0R2M)
$ 827.21 -6.645 (-0.8%) Market Cap: 91.15 Bil Enterprise Value: 84.05 Bil PE Ratio: 20.53 PB Ratio: 3.11 GF Score: 93/100

Regeneron Pharmaceuticals Inc to Share Updates on Hematology Portfolio Investor Event at ASH Transcript

Dec 13, 2021 / 09:30PM GMT
Release Date Price: $652.9 (-2.40%)
Operator

Good day, and thank you for standing by. Welcome to Regeneron's ASH 2021 Investor Event Conference Call. (Operator Instructions) Please note that this conference is being recorded. (Operator Instructions)

And now, I'd like to hand the conference over to your first speaker today, Mark Hudson, from Investor Relations. Thank you. Please go ahead.

Mark Hudson
Regeneron Pharmaceuticals, Inc. - IR Executive

Thank you. Welcome, everyone, to Regeneron's Oncology/Hematology ASH 2021 Webcast. Joining me on the call today are Dr. George Yancopoulos, Co-Founder, President and Chief Scientific Officer; Dr. Andres Sirulnik, Senior Vice President, Translational and Clinical Science, Hematology; Dr. Izzy Lowy, Senior Vice President of Translational and Science in Oncology. After our prepared remarks, we'll open up the call for Q&A.

Before handing the call over to George, I'd like to remind you that remarks made today include forward-looking statements about Regeneron, including those related to Regeneron's business and research and development programs,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot